The current top-recommended medications for restless leg syndrome (RLS) are gabapentin-type drugs, not the dopamine medications that dominated treatment for years. The American Academy of Sleep Medicine’s most recent clinical practice guideline gives its strongest recommendation to gabapentin enacarbil, standard gabapentin, and pregabalin as first-line treatments. This represents a significant shift from older guidelines that favored dopamine agonists, and the change was driven by concerns about long-term side effects those older drugs can cause.
Why Gabapentin-Type Drugs Are Now First Choice
Gabapentin enacarbil, regular gabapentin, and pregabalin all belong to a class called alpha-2-delta ligands. They work by calming overactive nerve signals rather than boosting dopamine. All three received strong recommendations backed by moderate-quality evidence, making them the closest thing to a consensus “best” option that exists in RLS treatment right now.
In head-to-head research, pregabalin outperformed the dopamine agonist pramipexole on several sleep measures. Patients on pregabalin spent about 27 fewer minutes awake after falling asleep compared to placebo, and had nearly identical improvements when compared against pramipexole. Pregabalin also increased deep sleep by about 32 minutes more than pramipexole and improved subjective total sleep time by roughly half an hour. Quality-of-life scores trended better with pregabalin as well, though the difference was modest.
The tradeoff is that these medications can cause dizziness and drowsiness, especially early on. In that same comparative trial, 61% of people on pregabalin experienced side effects versus 53% on pramipexole. Dizziness affected 24% of pregabalin users and sleepiness affected 17%. These effects often improve after the first few weeks.
Gabapentin enacarbil is specifically designed for RLS. It’s taken as a single 600 mg dose around 5 PM, timed so the drug peaks in the evening when symptoms are worst. Standard gabapentin is less predictably absorbed but works through the same mechanism and is more widely available.
What Happened to Dopamine Agonists
Dopamine agonists like pramipexole and ropinirole used to be the go-to prescriptions for RLS. They still work well in the short term. The problem is what happens over months and years: a phenomenon called augmentation, where the medication paradoxically makes RLS worse. Symptoms start earlier in the day, spread to the arms, or become more intense than they were before treatment began. About 6% of patients on dopamine agonists develop augmentation, compared to less than 1% of those on gabapentin or pregabalin. For the older drug levodopa, the rate climbs to 27%.
Dopamine agonists also carry a distinct risk of impulse control disorders. In a controlled study of 100 RLS patients taking these medications, 17% developed at least one compulsive behavior. That included compulsive eating (11%), compulsive shopping (9%), punding (repetitive purposeless activities, 7%), pathological gambling (5%), and hypersexuality (3%). Higher doses of pramipexole increased the risk, and these behaviors typically appeared around 9 to 10 months into treatment. Many patients don’t connect the new behavior to their medication, which can delay recognition.
A rotigotine patch is another dopamine agonist option, applied to the skin once daily at doses between 1 and 3 mg. It carries the same class-wide risks of augmentation and impulse control problems, plus common skin reactions like redness, itching, and rash at the patch site.
Check Your Iron Levels First
Before starting any medication, the single most important step is getting your iron levels tested. The relevant blood test is serum ferritin along with transferrin saturation. Even if your ferritin is technically “normal” by standard lab ranges, RLS specialists use a higher threshold: oral iron supplements are recommended when ferritin falls at or below 75 micrograms per liter. If ferritin is below 100 and you can’t tolerate oral iron (or it hasn’t worked), intravenous iron becomes an option.
Intravenous ferric carboxymaltose, given as a single 1,000 mg infusion, actually received a strong recommendation from the AASM as a treatment for moderate to severe RLS in patients whose iron stores are low enough to qualify. For some people, correcting iron deficiency resolves RLS entirely without the need for ongoing medication. Iron treatment should not be used if your transferrin saturation is above 45%, as this suggests your body already has adequate iron stores.
Things That Can Make RLS Worse
The AASM’s first good-practice recommendation is to identify and address factors that aggravate RLS before reaching for a prescription. Alcohol and caffeine are common culprits. Several widely used medications can also trigger or worsen symptoms, including antihistamines (found in many over-the-counter sleep aids and allergy pills), antidepressants that increase serotonin, and anti-nausea drugs that block dopamine. Untreated sleep apnea is another recognized trigger. Addressing these factors alone sometimes reduces symptoms enough to avoid medication.
Options for Severe or Hard-to-Treat RLS
When gabapentin-type drugs don’t provide adequate relief, or when someone has developed severe augmentation from years on dopamine agonists, low-dose opioids become a consideration. This is reserved for refractory cases and managed carefully, but the evidence supports it. Methadone has become the standard choice in this situation because its long duration of action matches the prolonged symptom window that augmented patients often experience, and once-daily dosing reduces misuse potential. Typical doses are low: the median in a long-term registry study was 7.5 mg of methadone daily.
Benzodiazepines like clonazepam are sometimes prescribed as well, though evidence for their use in RLS is limited. They don’t appear to directly treat the uncomfortable leg sensations. Instead, they help by reducing the time it takes to fall asleep and decreasing nighttime awakenings. Case series suggest some benefit, but the AASM does not recommend them as first-line treatment.
Kidney Function and Dose Adjustments
Because gabapentin and pregabalin are cleared through the kidneys, people with reduced kidney function need lower doses. This is especially relevant since RLS is common in people with chronic kidney disease. If your kidney filtration rate (eGFR) is between 30 and 60, pregabalin typically starts at 75 mg with a maximum of 300 mg daily. Below 30, the starting dose drops to 25 mg with a ceiling of 75 mg. Gabapentin follows a similar pattern of reduction. Your prescriber will adjust based on your lab results, but it’s worth knowing that standard doses listed online may not apply if you have any degree of kidney impairment.
Picking the Right Option
There is no single “best” medication that works for everyone with RLS. But the strongest current evidence points to gabapentin enacarbil, standard gabapentin, and pregabalin as the safest and most effective starting points for most adults. They control symptoms comparably to dopamine agonists in the short term while carrying far less risk of augmentation and compulsive behaviors over time. If your iron levels haven’t been checked, that should happen before or alongside any medication trial, since low iron is both a common and correctable driver of symptoms.